Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Currently 27.76% Below Its 52-week High But …

In last trading session, Collegium Pharmaceutical, Inc. (NASDAQ:COLL) saw 610,149 shares changing hands with its beta currently measuring 1.26. Company’s recent per share price level of $20.03 trading at $0.11 or 0.55% at ring of the bell on the day assigns it a market valuation of $692.68 Million. That closing price of COLL’s stock is at a discount of -27.76% from its 52-week high price of $25.59 and is indicating a premium of 35.1% from its 52-week low price of $13. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 233.97 Million shares which gives us an average trading volume of 264.4 Million if we extend that period to 3-months.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

For Collegium Pharmaceutical, Inc. (COLL), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.1. Splitting up the data highlights that, out of 10 analysts covering the stock, 1 rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 8 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0.31 in the current quarter.

Upright in the green today for gaining 0.55%, in the last five days COLL remained trading in the green while hitting it’s week-highest on Thursday, Dec 31 when the stock touched $20.23- price level, adding 0.99% to its value on the day. Collegium Pharmaceutical, Inc.’s shares saw a change of -2.67% in year-to-date performance and have moved 5.98% in past 5-day. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) showed a performance of 8.33% in past 30-days. Number of shares sold short was 3.92 Million shares which calculate 0.01 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $28.29 to the stock, which implies a rise of 41.24% to its current value. Analysts have been projecting $8 as a low price target for the stock while placing it at a high target of $38. It follows that stock’s current price would jump +89.72% in reaching the projected high whereas dropping to the targeted low would mean a loss of -60.06% for stock’s current value.

Collegium Pharmaceutical, Inc. (COLL) estimates and forecasts

Statistics highlight that Collegium Pharmaceutical, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added +14.72% of value to its shares in past 6 months, showing an annual growth rate of -225% while that of industry is 16.4. Apart from that, the company came raising its revenue forecast for fiscal year 2021. The company is estimating its revenue growth to increase by 542.9% in the current quarter and calculating 3900% increase in the next quarter. This year revenue growth is estimated to rise 5.1% from the last financial year’s standing.

8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $78.26 Million for the same. And 3 analysts are in estimates of company making revenue of $85.23 Million in the next quarter that will end in March 01, 2021. Company posted $74.2 Million and $76.51 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 5.5% while estimating it to be 11.4% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 5.7% during past 5 years. In 2021, company’s earnings growth rate is likely to be around 42.8% while estimates for its earnings growth in next 5 years are of 0.55%

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s Major holders

Insiders are in possession of 0.97% of company’s total shares while institution are holding 112.07% percent of that, with stock having share float percentage of 113.16%. Investors also watch the number of corporate investors in a company very closely, which is 211 institutions for Collegium Pharmaceutical, Inc. that are currently holding shares of the company. Janus Henderson Group PLC is the top institutional holder at COLL for having 5.12 Million shares of worth $106.65 Million. And as of September 29, 2020, it was holding 14.81% of the company’s outstanding shares.

The second largest institutional holder is Blackrock Inc., which was holding about 2.81 Million shares on September 29, 2020. The number of shares represents firm’s hold over 8.12% of outstanding shares, having a total worth of $58.48 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

On the other hand, Janus Henderson Contrarian Fund and Mutual Fund Ser Tr-Eventide Gilead Fund are the top two Mutual Funds which own company’s shares. As of September 29, 2020, the former fund manager was holding 2264477 shares of worth $47.15 Million or 6.55% of the total outstanding shares. The later fund manager was in possession of 1.34 Million shares on September 29, 2020, making its stake of worth around $27.99 Million in the company or a holder of 3.89% of company’s stock.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on.

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


Latest posts